RealSeq Biosciences
RealSeq Biosciences develops proprietary RNA fragmentomics library preparation kits and the RiboMarker AI-powered biomarker discovery platform, selling research-use reagents and sequencing services to academic labs, biotech firms, and diagnostics companies pursuing liquid biopsy and oncology applications.
- Company typePrivate
- Founded2019
- HeadquartersSanta Cruz, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What RealSeq Biosciences does
RealSeq Biosciences is a Santa Cruz, California-based private biotech founded in 2019 that develops proprietary RNA fragmentomics technology for small RNA and miRNA next-generation sequencing library preparation. Its core product, the RiboMarker platform, combines patented single-adapter and circularization library construction chemistry with next-generation sequencing on Illumina instruments and AI-powered bioinformatics to detect RNA fragments that conventional methods miss, claiming visibility into the approximately 90% of RNA not captured by traditional techniques. The company monetizes through direct e-commerce and purchase-order sales of three commercial kits (RealSeq-Biofluids for low-concentration samples, RealSeq-AC for tissue or cell samples, and RealSeq-Dual for combinatorial dual-index multiplexing), each priced between roughly $1,155 and $1,331, supplemented by sequencing services and customized bioinformatics offerings.
The company targets research institutions and academic labs, biotech and pharmaceutical companies, and diagnostics companies pursuing oncology, infectious disease, and liquid biopsy biomarker discovery. RealSeq has been primarily funded through non-dilutive NIH grants (including nearly $2M awarded in September 2025 and a Phase II NHGRI grant in November 2025), a $1.5M oversubscribed seed round in July 2023, and a March 2024 seed extension with Charleston Angel Partners, Santa Clara Ventures, and Santa Cruz Ventures. Leadership comprises CEO Sergio Barberan-Soler, founder and board member Brian H. Johnston, and COO Anne Scholz, with the company operating at 1-10 employees. RealSeq has stated an explicit strategic intent to prove clinical utility of its RNA biomarkers and pursue acquisition by a larger diagnostics firm, with active research collaborations including a partnership with the University of Gothenburg focused on oncology biomarker identification.
RealSeq Biosciences firmographics
Firmographics- Name
- RealSeq Biosciences
- Legal name
- RealSeq Biosciences
- Website
- https://realseqbiosciences.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- RealSeq Biosciences develops proprietary RNA fragmentomics library preparation kits and the RiboMarker AI-powered biomarker discovery platform, selling research-use reagents and sequencing services to academic labs, biotech firms, and diagnostics companies pursuing liquid biopsy and oncology applications.
- Ownership category
- akta.pro rank
RealSeq Biosciences industry classification
Industry- Product category
- RNA Sequencing Reagents
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
- akta.pro secondary industries
- Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
Keywords
Where RealSeq Biosciences is headquartered
LocationHeadquarters
- HQ city
- Santa Cruz
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
RealSeq Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- RNA NGS Library Preparation Kits: Sale of proprietary small RNA library preparation kits (RealSeq-Biofluids, RealSeq-AC, RealSeq-Dual) for Illumina sequencing platforms. Kits are available in 12 or 48 reaction formats with barcoding capabilities.
- Sequencing Services: RNA sequencing services provided from extracted RNA or ready-to-sequence pooled libraries, along with customized bioinformatics analysis services.
- Technology Licensing: The company aims to prove clinical utility and seek acquisition by a larger diagnostics firm, indicating potential future licensing of their RNA biomarker technology.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | RealSeq-Biofluids Small RNA Library Preparation Kit - for biofluids and low concentration samples |
| Unit Pricing | Pay-as-you-go | RealSeq-AC Small RNA Library Preparation Kit - for tissue or cell samples |
| Unit Pricing | Pay-as-you-go | RealSeq-Dual Small RNA Library Preparation Kit - with dual barcoding |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
RealSeq Biosciences product offering
Product offeringCore offering
RealSeq Biosciences develops and sells small RNA next-generation sequencing (NGS) library preparation kits and the proprietary RiboMarker platform, which combines patented single-adapter and circularization library construction chemistry, NGS, and AI-powered bioinformatics to discover RNA biomarkers from biofluids, tissues, and cells for diagnostic and liquid biopsy applications.
Product overview
RealSeq Biosciences offers the RiboMarker platform for RNA biomarker discovery combined with a portfolio of RNA next-generation sequencing products. The RiboMarker platform is a proprietary technology that analyzes RNA fragments using library construction, NGS, and AI-powered bioinformatics to uncover novel biomarkers for liquid biopsy and diagnostic applications. This platform is complemented by commercial library preparation kits including the RealSeq-Biofluids kit for biofluid samples, the RealSeq-AC kit for tissue/cell samples, and the RealSeq-Dual kit with dual barcoding capability for enhanced multiplexing—all designed for Illumina sequencing platforms.
Differentiator
Problem solved
Functional benefit
Brands
- RiboMarker®: Proprietary platform for RNA biomarker discovery that analyzes RNA fragments through library construction, NGS, and AI-powered bioinformatics tools for diagnostic applications
- RealSeq®-Biofluids
- RealSeq®-AC
- RealSeq® Dual
Products and services
- RiboMarker Platform A proprietary RNA biomarker discovery platform that uncovers novel biomarkers by analyzing RNA fragments that other approaches cannot detect through a combination of library construction, next-generation sequencing, and AI-powered bioinformatics tools for liquid biopsy and diagnostic applications.
- RealSeq-Biofluids Small RNA Library Preparation Kit Complete small RNA library preparation kit for Illumina for RNA samples from biofluids and other low concentration samples, featuring patented single-adapter and circularization technology to reduce detection bias. Each kit includes size selection reagent and barcoded PCR primers.
- RealSeq-AC Small RNA Library Preparation Kit Complete small RNA library preparation kit for Illumina for RNA samples from tissues or cells, supporting 1 ng to 1000 ng total RNA input with patented single-adapter and circularization technology. Each kit includes size selection reagent and barcoded PCR primers.
- RealSeq-Dual Small RNA Library Preparation Kit Complete small RNA library preparation kit for Illumina with dual barcoding capability using combinatorial dual indexing, supporting up to 384 unique combinations for advanced multiplexing for samples from tissues, cells, or biofluids.
- RNA Sequencing and Bioinformatics Services RNA sequencing services offered from extracted RNA or ready-to-sequence pooled libraries, along with customized bioinformatics analysis services for researchers requiring end-to-end small RNA profiling and biomarker discovery support.
Quantifiable outcome
- Platform can detect the other 90% of RNA that current techniques only see about 10% of
Companies that use RealSeq Biosciences
Customer profileSegments3 records
Ideal customer profiles3 records
RealSeq Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability2 records
Feature6 records
RealSeq Biosciences partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- University of GothenburgcoreResearch collaboration with The University of Gothenburg to explore potential of RNA analysis technology for identifying disease biomarkers, particularly in oncology.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
RealSeq Biosciences competitors and assessment
Company assessmentEmerging players
- Element Biosciences: Element Biosciences (AVITI sequencer) is an emerging alternative NGS platform vendor challenging Illumina. It is not a direct library prep competitor but represents both a future re-validation opportunity and a competitive threat to Illumina-locked kits like RealSeq's.
- NanoString Technologies (now part of Bruker): NanoString's nCounter platform and GeoMx digital spatial profiling are used for RNA expression and biomarker discovery in translational labs. It overlaps with RealSeq's biomarker-discovery customer base but uses a fundamentally different detection chemistry.
- HTG Molecular Diagnostics: HTG Molecular offers RNA expression profiling technologies (HTG EdgeSeq) used for biomarker discovery and translational research. It targets the same translational research customer that RealSeq is pursuing with RiboMarker, making it a partial-overlap emerging peer.
Others
- Revvity (formerly PerkinElmer): Revvity's life sciences segment sells NGS library prep reagents and automation, and previously distributed small RNA kits via the Bioo Scientific line. It is a comparable NGS consumables vendor with scale advantages over RealSeq and a potential strategic acquirer.
Direct peers
- New England Biolabs (NEB): NEB's NEBNext line is the dominant NGS library prep franchise, including small RNA library prep kits. It competes with RealSeq on bench preference and is the entrenched incumbent RealSeq must displace or co-exist with on researcher shopping lists.
- Lexogen: Lexogen sells small RNA/miRNA library preparation kits (e.g., Small RNA-Seq Library Prep Kit) for Illumina and other platforms. It is the most direct head-to-head competitor to RealSeq's RealSeq-Biofluids and RealSeq-AC kits in the small RNA library prep market.
- Takara Bio: Takara Bio offers small RNA-seq library prep kits (SMARTer) and a broad NGS reagent portfolio. It competes directly with RealSeq for academic and translational researchers purchasing small RNA library preparation consumables.
Broad incumbents
- Illumina: Illumina sells TruSeq small RNA library prep kits and dominates the sequencing platform ecosystem on which RealSeq's kits run. Illumina is both a critical platform partner and a competing kit supplier, and represents both RealSeq's largest dependency and a likely acquisition candidate.
- Qiagen: Qiagen's QIAseq small RNA library prep kits and broader sample-prep portfolio compete with RealSeq at the bench. As a much larger life-science tools company with global reach, Qiagen is also a plausible acquirer for RealSeq's RNA fragmentomics IP.
- Thermo Fisher Scientific: Thermo Fisher sells Ion Torrent library prep kits and a wide range of molecular biology reagents. As the largest life-science tools company, it competes indirectly with RealSeq and represents the most likely large strategic acquirer for an emerging RNA fragmentomics platform.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
RealSeq Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
RealSeq Biosciences leadership team
Management profileNumber of profiles
Profiles3 records
RealSeq Biosciences funding detail
Funding detailFunding overview
Funding rounds4 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RealSeq Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RealSeq Biosciences
What does RealSeq Biosciences do?
RealSeq Biosciences develops and sells small RNA next-generation sequencing (NGS) library preparation kits and the proprietary RiboMarker platform, which combines patented single-adapter and circularization library construction chemistry, NGS, and AI-powered bioinformatics to discover RNA biomarkers from biofluids, tissues, and cells for diagnostic and liquid biopsy applications.
Is RealSeq Biosciences a public or private company?
RealSeq Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was RealSeq Biosciences founded?
RealSeq Biosciences was founded in 2019. It employs 1 to 10 people.
Where is RealSeq Biosciences based?
RealSeq Biosciences is headquartered in Santa Cruz, United States, in the North America region.
How does RealSeq Biosciences make money?
Three revenue lines are on record. RNA NGS Library Preparation Kits are the primary driver. The others are sequencing Services and technology Licensing.
Who are RealSeq Biosciences's main competitors?
Emerging players on record are Element Biosciences, NanoString Technologies (now part of Bruker) and HTG Molecular Diagnostics. Revvity (formerly PerkinElmer) is listed as an others. Direct peers are New England Biolabs (NEB), Lexogen and Takara Bio. Broad incumbents are Illumina, Qiagen and Thermo Fisher Scientific.
Does RealSeq Biosciences have an API?
No public API is recorded for RealSeq Biosciences.
What industry is RealSeq Biosciences in?
RealSeq Biosciences's product category is RNA Sequencing Reagents. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays), with a secondary code of HLAGANAE, Transcriptomics & Gene Expression Profiling Services. Its NAICS code is 541714 and its SIC code is 2835.